FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895895576> ?p ?o ?g. }

• W2895895576 endingPage "862" @default.
• W2895895576 startingPage "855" @default.
• W2895895576 abstract "Background The RAISE study showed that additional prednisolone improved coronary artery outcomes in patients with Kawasaki disease at high risk of intravenous immunoglobulin (IVIG) resistance. However, no studies have been done to test the steroid regimen used in the RAISE study. We therefore aimed to verify the efficacy and safety of primary IVIG plus prednisolone. Methods We did a multicentre, prospective cohort study at 34 hospitals in Japan. We included patients diagnosed with Kawasaki disease according to the Japanese diagnostic criteria, and excluded those who were treated at other hospitals before being transferred to a participating hospital. Patients who were febrile at diagnosis received primary IVIG (2 g/kg per 24 h) and oral aspirin (30 mg/kg per day) until the fever resolved, followed by oral aspirin (5 mg/kg per day) for 2 months after Kawasaki disease onset. We stratified patients using the Kobayashi score into predicted IVIG non-responders (Kobayashi score ≥5) or predicted IVIG responders (Kobayashi score <5). For predicted non-responders, each hospital independently decided whether to add prednisolone (intravenous injection of 2 mg/kg per day for 5 days) to the primary IVIG treatment, according to their respective treatment policy, and we further divided these patients based on the primary treatment received. The primary endpoint was the incidence of coronary artery abnormalities determined by two-dimensional echocardiography at 1 month after the primary treatment in predicted non-responders treated with primary IVIG plus prednisolone. Coronary artery abnormalities were defined according to the criteria of the Japanese Ministry of Health and Welfare and of the American Heart Association (AHA). This study is registered with the University Hospital Medical Information Network Clinical Trials Registry, number UMIN000007133. Findings From July 1, 2012, to June 30, 2015, we enrolled 2628 patients with Kawasaki disease, of whom 724 (27·6%) were predicted IVIG non-responders who received IVIG plus prednisolone as primary treatment. 132 (18·2%) of 724 patients did not respond to primary treatment. Among patients with complete data, coronary artery abnormalities were present in 40 (incidence rate 5·9%, 95% CI 4·3–8·0) of 676 patients according to the AHA criteria or in 26 (3·8%, 2·5–5·6) of 677 patients according to the Japanese criteria. Serious adverse events were reported in 12 (1·7%) of 724 patients treated with primary IVIG plus prednisolone; two of these patients had hypertension and bacteraemia that was probably related to prednisolone. One patient died possibly due to severe inflammation from the Kawasaki disease itself. Interpretation Primary IVIG plus prednisolone therapy in this study had an effect similar to that seen in the RAISE study in reducing the non-response rate and decreasing the incidence of coronary artery abnormalities. A primary IVIG and prednisolone combination therapy might prevent coronary artery abnormalities and contribute to lowering medical costs. Funding Tokyo Metropolitan Government Hospitals and the Japan Kawasaki Disease Research Center." @default.
• W2895895576 created "2018-10-26" @default.
• W2895895576 creator A5001659211 @default.
• W2895895576 creator A5028156252 @default.
• W2895895576 creator A5030179420 @default.
• W2895895576 creator A5038758701 @default.
• W2895895576 creator A5039599229 @default.
• W2895895576 creator A5041543619 @default.
• W2895895576 creator A5043409474 @default.
• W2895895576 creator A5044228267 @default.
• W2895895576 creator A5045604229 @default.
• W2895895576 creator A5046402616 @default.
• W2895895576 creator A5065151966 @default.
• W2895895576 creator A5065371004 @default.
• W2895895576 creator A5065615311 @default.
• W2895895576 creator A5081460416 @default.
• W2895895576 creator A5084199594 @default.
• W2895895576 creator A5088238265 @default.
• W2895895576 creator A5089859687 @default.
• W2895895576 date "2018-12-01" @default.
• W2895895576 modified "2023-10-10" @default.
• W2895895576 title "Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study" @default.
• W2895895576 cites W1494703858 @default.
• W2895895576 cites W1933208763 @default.
• W2895895576 cites W1976197580 @default.
• W2895895576 cites W1985527818 @default.
• W2895895576 cites W2014440960 @default.
• W2895895576 cites W2020009342 @default.
• W2895895576 cites W2071347890 @default.
• W2895895576 cites W2092491495 @default.
• W2895895576 cites W2109450728 @default.
• W2895895576 cites W2119962795 @default.
• W2895895576 cites W2126696221 @default.
• W2895895576 cites W2329101550 @default.
• W2895895576 cites W2410862888 @default.
• W2895895576 cites W2418455929 @default.
• W2895895576 cites W2518725271 @default.
• W2895895576 cites W2601489012 @default.
• W2895895576 cites W2604027935 @default.
• W2895895576 cites W2606588809 @default.
• W2895895576 cites W2620209822 @default.
• W2895895576 cites W4211236826 @default.
• W2895895576 cites W4244865467 @default.
• W2895895576 cites W4255017270 @default.
• W2895895576 doi "https://doi.org/10.1016/s2352-4642(18)30293-1" @default.
• W2895895576 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30337183" @default.
• W2895895576 hasPublicationYear "2018" @default.
• W2895895576 type Work @default.
• W2895895576 sameAs 2895895576 @default.
• W2895895576 citedByCount "60" @default.
• W2895895576 countsByYear W28958955762018 @default.
• W2895895576 countsByYear W28958955762019 @default.
• W2895895576 countsByYear W28958955762020 @default.
• W2895895576 countsByYear W28958955762021 @default.
• W2895895576 countsByYear W28958955762022 @default.
• W2895895576 countsByYear W28958955762023 @default.
• W2895895576 crossrefType "journal-article" @default.
• W2895895576 hasAuthorship W2895895576A5001659211 @default.
• W2895895576 hasAuthorship W2895895576A5028156252 @default.
• W2895895576 hasAuthorship W2895895576A5030179420 @default.
• W2895895576 hasAuthorship W2895895576A5038758701 @default.
• W2895895576 hasAuthorship W2895895576A5039599229 @default.
• W2895895576 hasAuthorship W2895895576A5041543619 @default.
• W2895895576 hasAuthorship W2895895576A5043409474 @default.
• W2895895576 hasAuthorship W2895895576A5044228267 @default.
• W2895895576 hasAuthorship W2895895576A5045604229 @default.
• W2895895576 hasAuthorship W2895895576A5046402616 @default.
• W2895895576 hasAuthorship W2895895576A5065151966 @default.
• W2895895576 hasAuthorship W2895895576A5065371004 @default.
• W2895895576 hasAuthorship W2895895576A5065615311 @default.
• W2895895576 hasAuthorship W2895895576A5081460416 @default.
• W2895895576 hasAuthorship W2895895576A5084199594 @default.
• W2895895576 hasAuthorship W2895895576A5088238265 @default.
• W2895895576 hasAuthorship W2895895576A5089859687 @default.
• W2895895576 hasConcept C120665830 @default.
• W2895895576 hasConcept C121332964 @default.
• W2895895576 hasConcept C126322002 @default.
• W2895895576 hasConcept C141071460 @default.
• W2895895576 hasConcept C187212893 @default.
• W2895895576 hasConcept C188816634 @default.
• W2895895576 hasConcept C203092338 @default.
• W2895895576 hasConcept C2776715498 @default.
• W2895895576 hasConcept C2776820930 @default.
• W2895895576 hasConcept C2777628954 @default.
• W2895895576 hasConcept C2778720950 @default.
• W2895895576 hasConcept C2781413609 @default.
• W2895895576 hasConcept C2781423770 @default.
• W2895895576 hasConcept C535046627 @default.
• W2895895576 hasConcept C61511704 @default.
• W2895895576 hasConcept C71924100 @default.
• W2895895576 hasConcept C72563966 @default.
• W2895895576 hasConceptScore W2895895576C120665830 @default.
• W2895895576 hasConceptScore W2895895576C121332964 @default.
• W2895895576 hasConceptScore W2895895576C126322002 @default.
• W2895895576 hasConceptScore W2895895576C141071460 @default.
• W2895895576 hasConceptScore W2895895576C187212893 @default.
• W2895895576 hasConceptScore W2895895576C188816634 @default.
• W2895895576 hasConceptScore W2895895576C203092338 @default.

• next